Low Oxygen Inside Tumors Fuels Cervical Cancer Growth and Cisplatin Resistance, Study Finds

Cervical cancer remains one of the most stubborn global health challenges, and a new study published in the Journal of Translational Medicine has uncovered a molecular chain of events that helps explain why some tumors grow aggressively and shrug off chemotherapy. A research team led by Qian Li, Mengxin Sun and Yan Zhang at Chongqing Medical University, working with colleagues at Chongqing Three Gorges Medical College, reports that low-oxygen conditions inside tumors—a state known as hypoxia—switch off a gene called CCNDBP1, and that this single molecular change sets off a cascade that promotes cancer spread and resistance to cisplatin, one of the most widely used chemotherapy drugs for the disease.

The investigation began with a large-scale computational screen. The researchers mined data from The Cancer Genome Atlas (TCGA), the Gene Expression Omnibus (GEO) and the GEPIA web platform, searching for genes whose activity tracks with patient outcomes in cervical cancer. CCNDBP1, a gene better known for its role in cell-cycle control, stood out: it was downregulated not only in cervical cancer but across most human cancers examined, and lower levels of the gene correlated with poorer overall survival and reduced sensitivity to cisplatin in the analyzed cohorts. That pattern suggested CCNDBP1 might act as a tumor suppressor whose loss gives cancer cells an advantage—particularly in the oxygen-starved interiors of solid tumors.

To test whether hypoxia itself was responsible for silencing CCNDBP1, the team exposed cervical cancer cells to several independent models of oxygen deprivation. They grew the cells under 1 percent oxygen, treated them with cobalt chloride—a chemical that mimics hypoxic signaling—and forced the expression of HIF-1α, the master transcription factor that cells deploy when oxygen levels fall. All three approaches drove CCNDBP1 down, confirming that the gene is a direct casualty of the hypoxic program. The mechanism turned out to be indirect but elegant: hypoxia activates HIF-1α, which transcriptionally upregulates a microRNA called miR-9-5p, and this small RNA molecule in turn suppresses CCNDBP1 expression.

With CCNDBP1 knocked down, the researchers mapped what happened next inside the cell. Using chromatin immunoprecipitation (ChIP), CUT&RUN, dual-luciferase reporter assays and molecular docking, they showed that CCNDBP1 normally restrains the transcription factor E2F1. When CCNDBP1 levels fall, that brake is released, E2F1 becomes more active, and E2F1 drives up the transcription of USP11, a deubiquitinating enzyme. In other words, losing one tumor suppressor switches on a ubiquitin-editing machinery that the cell does not actually need—or, from the cancer’s perspective, very much wants.

The consequences of elevated USP11 proved central to the study. Ubiquitin tags, particularly K48-linked polyubiquitin chains, mark proteins for destruction by the proteasome. USP11 strips those tags off Nrf2, the chief regulator of the cellular antioxidant response. By removing K48-linked ubiquitin from Nrf2, USP11 stabilizes the protein, promotes its movement into the nucleus, and amplifies the downstream antioxidant stress program. Co-immunoprecipitation experiments confirmed the physical interaction between USP11 and Nrf2, while Western blotting and quantitative PCR traced the signaling steps along the entire axis from HIF-1α through miR-9-5p, CCNDBP1, E2F1 and USP11 to Nrf2.

Why would boosting antioxidant defenses make a tumor more dangerous? The answer lies in how cisplatin works. The drug kills cancer cells largely by generating reactive oxygen species (ROS) and inflicting DNA damage. A tumor cell with a hyperactive Nrf2 pathway is essentially wearing chemical armor: it neutralizes oxidative stress before the drug can push it over the lethal threshold. The team measured this directly with a battery of functional assays, including ROS quantification, total antioxidant capacity (T-AOC) testing, glutathione-to-oxidized-glutathione (GSH/GSSG) ratio measurements and the comet assay for DNA strand breaks. Cells with low CCNDBP1 showed the hallmarks of a fortified antioxidant state and correspondingly higher IC50 values for cisplatin, meaning more drug was needed to achieve the same kill.

The pro-metastatic side of the story was equally striking. Using CCK-8 proliferation assays, flow cytometry, Transwell migration and invasion chambers, and immunofluorescence imaging, the researchers demonstrated that silencing CCNDBP1 enhanced the malignant behaviors of cervical cancer cells—faster growth, reduced cell death, and greater capacity to migrate and invade. Restoring CCNDBP1, or interfering with the USP11–Nrf2 axis, reversed these effects, providing evidence that the pathway is not merely correlated with aggression but functionally drives it. RNA sequencing of the manipulated cells further supported the wiring of the proposed circuit.

The study’s conclusions rest on preclinical models, and the authors are careful to frame it that way: they characterize CCNDBP1 as a biologically relevant modulator of metastatic capacity and cellular cisplatin responsiveness based on those models, and position the work as a foundation for future investigations into the clinical significance of the pathway. The research was approved by the Ethics Committee of Chongqing Medical University and conducted under institutional animal care guidelines, with written informed consent obtained from all participants whose tissue specimens were used. The work was funded by the Science and Technology Research Program of the Chongqing Municipal Education Commission.

Translational implications follow naturally from the mechanism. If hypoxia-driven loss of CCNDBP1 is what arms tumors against cisplatin, then each node of the HIF-1α–miR-9-5p–CCNDBP1–USP11–Nrf2 axis becomes a potential point of intervention. Inhibiting USP11’s deubiquitinase activity, blocking Nrf2 nuclear translocation, or restoring CCNDBP1 function could in principle resensitize resistant tumors to platinum chemotherapy, while CCNDBP1 expression levels might serve as a biomarker to identify patients likely to benefit from cisplatin in the first place. None of these applications has yet been tested in patients, but the study provides the mechanistic roadmap that such efforts would require.

For a disease that still imposes a heavy burden worldwide, the findings add a genuinely new piece to the puzzle of treatment failure. They connect a physical feature of the tumor microenvironment—oxygen starvation—to a specific genetic casualty, and trace an unbroken molecular line from that event to chemotherapy resistance and metastatic behavior. As the authors note, the work extends understanding of the molecular circuits governing cervical cancer progression, and it does so by revealing that a tumor’s hostile interior is not just a byproduct of rapid growth but an active architect of the cancer’s defenses.

Subject of Research: Hypoxia-driven CCNDBP1 downregulation and the USP11–Nrf2 axis in cervical cancer progression and cisplatin resistance

Article Title: Hypoxia-mediated downregulation of CCNDBP1 facilitates cervical cancer progression and cisplatin resistance through the USP11-Nrf2 axis

Article References: Li, Q., Sun, M., He, X., Li, X., You, Y., Dang, T., Sun, H., Zhang, L., Ren, R., Liu, J., Tang, J., & Zhang, Y. (2026). Hypoxia-mediated downregulation of CCNDBP1 facilitates cervical cancer progression and cisplatin resistance through the USP11-Nrf2 axis. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-09008-x

Image Credits: AI Generated

DOI: 10.1186/s12967-026-09008-x

Keywords: cervical cancer, hypoxia, CCNDBP1, HIF-1α, miR-9-5p, USP11, Nrf2, cisplatin resistance, deubiquitination, tumor microenvironment, oxidative stress, Journal of Translational Medicine